Combating influenza with antiviral therapy in the pediatric population

Area of Science:

• Pediatric Infectious Diseases
• Virology
• Pharmacology

Background:

• Influenza causes annual epidemics with significant global morbidity and mortality.
• Children aged 0-18 years experience high infection rates (15-42%) and are key transmitters in communities.
• Two antiviral classes, adamantanes and neuraminidase inhibitors, are approved for pediatric influenza treatment and prophylaxis.

Purpose of the Study:

• To review the safety and efficacy of approved antiviral agents for pediatric influenza.
• To compare the mechanisms of action, adverse effects, and resistance profiles of adamantanes and neuraminidase inhibitors.
• To emphasize that antiviral therapy complements, but does not replace, annual influenza vaccination.

Main Methods:

• Literature review of clinical trials and surveillance data on pediatric influenza.
• Analysis of approved antiviral drugs: amantadine, rimantadine, zanamivir, and oseltamivir.
• Examination of drug class differences in efficacy, safety, and resistance.

Main Results:

• Antiviral therapy initiated within 48 hours of symptom onset reduces illness duration and expedites return to daily activities.
• Adamantanes and neuraminidase inhibitors exhibit distinct mechanisms of action, side effect profiles, and resistance patterns.
• No direct head-to-head clinical trials comparing neuraminidase inhibitors or comparing the two drug classes were identified.

Conclusions:

• Amantadine, rimantadine, zanamivir, and oseltamivir are safe and effective for treating influenza in children.
• Early antiviral treatment shortens illness and facilitates a quicker return to normal activities.
• Antiviral medications are an important adjunct to, not a substitute for, annual influenza vaccination.